Vicore Pharma Holding AB (OSTO:VICO) Total Liabilities: kr86.35 Mil (As of Mar. 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
30 GF Score
Price kr12.08
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Total Liabilities?

Vicore Pharma Holding AB OSTO:VICO -4.13% 30 Total Liabilities is kr86.35 Mil as of Mar. 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Vicore Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr86.35 Mil.

Vicore Pharma Holding AB's quarterly Total Liabilities increased from Sep. 2025 (kr68.07 Mil) to Dec. 2025 (kr123.18 Mil) but then declined from Dec. 2025 (kr123.18 Mil) to Mar. 2026 (kr86.35 Mil).

Vicore Pharma Holding AB's annual Total Liabilities increased from Dec. 2023 (kr42.45 Mil) to Dec. 2024 (kr66.25 Mil) and increased from Dec. 2024 (kr66.25 Mil) to Dec. 2025 (kr123.18 Mil).


Vicore Pharma Holding AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Total Liabilities Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.85 48.92 42.45 66.25 123.18

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.08 68.25 68.07 123.18 86.35
OSTO:VICO
30GF Score
Vicore Pharma Holding AB OSTO:VICO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vicore Pharma Holding AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=118.434+(0+4.741
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=123.18

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1218.637-1095.462
=123.18

Vicore Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1077.265-990.911
=86.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr86.35 Mil mean?
Vicore Pharma Holding AB (OSTO:VICO) has a Total Liabilities of kr86.35 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Total Liabilities too high?
Vicore Pharma Holding AB's current Total Liabilities is kr86.35 Mil. Overall, Vicore Pharma Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Total Liabilities compare to VRTX and REGN?
Vicore Pharma Holding AB's Total Liabilities of kr86.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Total Liabilities is kr86.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Total Liabilities of kr86.35 Mil. The current Total Liabilities is kr86.35 Mil. Vicore Pharma Holding AB's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Total Liabilities is kr86.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score

Get the complete analysis for OSTO:VICO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.08
Price